BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berthelot JM, De Bandt M, Goupille P, Solau-Gervais E, Lioté F, Goeb V, Azaïs I, Martin A, Pallot-Prades B, Maugars Y. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine. 2009;76:28-34. [PMID: 19059799 DOI: 10.1016/j.jbspin.2008.04.016] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Crijns HJ, Jentink J, Garne E, Gispen-de Wied CC, Straus SM, de Jong-van den Berg LT. The Distribution of Congenital Anomalies Within the VACTERL Association Among Tumor Necrosis Factor Antagonist-exposed Pregnancies Is Similar to the General Population. J Rheumatol 2011;38:1871-4. [DOI: 10.3899/jrheum.101316] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
2 Osting VC, Carter JD. A safety assessment of tumor necrosis factor antagonists during pregnancy. Expert Opin Drug Saf. 2010;9:421-429. [PMID: 20367495 DOI: 10.1517/14740330903578639] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
3 Seifarth C, Ritz JP, Pohlen U, Kroesen AJ, Siegmund B, Frericks B, Buhr HJ. Therapy of complicated Crohn's disease during pregnancy--an interdisciplinary challenge. Int J Colorectal Dis 2014;29:645-51. [PMID: 24793212 DOI: 10.1007/s00384-014-1880-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
4 Delgado Frías E, Díaz González JF. [Certolizumab pegol]. Reumatol Clin 2011;6S3:S7-11. [PMID: 21794764 DOI: 10.1016/j.reuma.2010.11.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
5 Ergaz Z, Bar-Oz B, Vainer GW, Abu-Leil S, Simanovsky N, Diav-Citrin O. Congenital fulminant Kaposiform hemangioendothelioma of the leg. Reprod Toxicol. 2014;50:1-3. [PMID: 25277314 DOI: 10.1016/j.reprotox.2014.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, Ozawa A, Kanekura T, Kurosawa M, Komine M, Nakajima K, Sano S, Nemoto O, Muto M, Imai Y, Yamanishi K, Aoyama Y, Iwatsuki K; The Japanese Dermatological Association Guidelines Development Committee for the Guidelines for the Management and Treatment of Generalized Pustular Psoriasis. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP. J Dermatol 2018;45:1235-70. [DOI: 10.1111/1346-8138.14523] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 12.7] [Reference Citation Analysis]
7 Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis. 2010;16:881-895. [PMID: 19885906 DOI: 10.1002/ibd.21154] [Cited by in Crossref: 102] [Cited by in F6Publishing: 74] [Article Influence: 9.3] [Reference Citation Analysis]
8 Østensen M, Förger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol. 2009;5:382-390. [PMID: 19506586 DOI: 10.1038/nrrheum.2009.103] [Cited by in Crossref: 91] [Cited by in F6Publishing: 71] [Article Influence: 7.6] [Reference Citation Analysis]
9 Peluso R, Cafaro G, Di Minno A, Iervolino S, Ambrosino P, Lupoli G, Di Minno MN. Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies. Clin Rheumatol 2013;32:743-53. [PMID: 23588881 DOI: 10.1007/s10067-013-2252-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
10 Mansouri B, Patel M, Menter A. Biological therapies for psoriasis. Expert Opin Biol Ther. 2013;13:1715-1730. [PMID: 24160990 DOI: 10.1517/14712598.2013.853739] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
11 Østensen M. Therapy: are TNF inhibitors safe in pregnancy? Nat Rev Rheumatol 2009;5:184-5. [PMID: 19337279 DOI: 10.1038/nrrheum.2009.47] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
12 Carpentier PA, Dingman AL, Palmer TD. Placental TNF-α signaling in illness-induced complications of pregnancy. Am J Pathol 2011;178:2802-10. [PMID: 21641402 DOI: 10.1016/j.ajpath.2011.02.042] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
13 Lund T, Thomsen SF. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series. Dermatol Ther 2017;30. [PMID: 28071837 DOI: 10.1111/dth.12454] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
14 Barenbrug L, Groen MT, Hoentjen F, van Drongelen J, Reek JMPAVD, Joosten I, de Jong EMGJ, van der Molen RG. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-α during pregnancy: A systemic review and meta-analysis. J Autoimmun 2021;122:102676. [PMID: 34126302 DOI: 10.1016/j.jaut.2021.102676] [Reference Citation Analysis]
15 Djokanovic N, Klieger-Grossmann C, Pupco A, Koren G. Safety of infliximab use during pregnancy. Reprod Toxicol. 2011;32:93-97. [PMID: 21621603 DOI: 10.1016/j.reprotox.2011.05.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
16 Alijotas-reig J, Esteve-valverde E, Ferrer-oliveras R, Llurba E, Gris JM. Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. Clinic Rev Allerg Immunol 2017;53:40-53. [DOI: 10.1007/s12016-016-8596-x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 17.5] [Reference Citation Analysis]
17 Önalan G, Tohma YA, Zeyneloğlu HB. Effect of Etanercept on the Success of Assisted Reproductive Technology in Patients with Endometrioma. Gynecol Obstet Invest 2018;83:358-64. [PMID: 29208847 DOI: 10.1159/000484895] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
18 Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol. 2013;19:2591-2602. [PMID: 23674866 DOI: 10.3748/wjg.v19.i17.2591] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 55] [Article Influence: 10.0] [Reference Citation Analysis]
19 Dessinioti C, Stefanaki I, Stratigos AJ, Kostaki M, Katsambas A, Antoniou C. Pregnancy during adalimumab use for psoriasis. J Eur Acad Dermatol Venereol. 2011;25:738-739. [PMID: 20569288 DOI: 10.1111/j.1468-3083.2010.03756.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
20 Bangsgaard N, Rørbye C, Skov L. Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. Am J Clin Dermatol 2015;16:389-98. [PMID: 26149091 DOI: 10.1007/s40257-015-0137-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
21 Romero R, Kadar N, Vaisbuch E, Hassan SS. Maternal death following cardiopulmonary collapse after delivery: amniotic fluid embolism or septic shock due to intrauterine infection? Am J Reprod Immunol 2010;64:113-25. [PMID: 20236259 DOI: 10.1111/j.1600-0897.2010.00823.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
22 Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient. Journal of the American Academy of Dermatology 2019;80:43-53. [DOI: 10.1016/j.jaad.2018.06.056] [Cited by in Crossref: 119] [Cited by in F6Publishing: 84] [Article Influence: 59.5] [Reference Citation Analysis]
23 Alijotas-reig J. Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus 2013;22:6-17. [DOI: 10.1177/0961203312465782] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
24 Zrour-hassen S, Jguirim M, Aouam K, Korbaa W, Younes M, Bejia I, Touzi M, Bergaoui N. Sécurité des médicaments à usage rhumatologique en âge de procréation. Therapies 2010;65:465-73. [DOI: 10.2515/therapie/2010061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Raja H, Matteson EL, Michet CJ, Smith JR, Pulido JS. Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding. Transl Vis Sci Technol 2012;1:6. [PMID: 24049706 DOI: 10.1167/tvst.1.2.6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
26 Geyer M, Müller-Ladner U. Rationale of using different biological therapies in rheumatoid arthritis. Arthritis Res Ther 2010;12:214. [PMID: 20735862 DOI: 10.1186/ar3102] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
27 Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M, Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A, Schaeverbeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011;78 Suppl 1:15-185. [PMID: 21703545 DOI: 10.1016/S1297-319X(11)70001-X] [Cited by in Crossref: 53] [Cited by in F6Publishing: 6] [Article Influence: 5.3] [Reference Citation Analysis]
28 Hoxha A, Calligaro A, Di Poi E, Peccatori S, Favaro M, Del Ross T, Ramonda R, Grava C, Raffeiner B, Ravagni P, De Vita S, Ruffatti A. Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study. Joint Bone Spine 2017;84:169-73. [DOI: 10.1016/j.jbspin.2016.03.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
29 Leung Y, Panaccione R, Ghosh S, Seow CH. Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions. Can J Gastroenterol Hepatol 2014;28:505-9. [PMID: 25101334 DOI: 10.1155/2014/967598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
30 Yiu ZZ, Griffiths CE, Warren RB. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. Br J Dermatol. 2014;171:485-491. [PMID: 24749725 DOI: 10.1111/bjd.13060] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
31 Burmester GR, Landewé R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2017;76:414-7. [PMID: 27338778 DOI: 10.1136/annrheumdis-2016-209322] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 13.6] [Reference Citation Analysis]
32 Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426-1438. [PMID: 23752881 DOI: 10.1038/ajg.2013.171] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 10.5] [Reference Citation Analysis]
33 Krause ML, Amin S, Makol A. Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know. Ther Adv Musculoskelet Dis 2014;6:169-84. [PMID: 25342996 DOI: 10.1177/1759720X14551568] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
34 Wan J, Imadojemu S, Werth VP. Management of rheumatic and autoimmune blistering disease in pregnancy and postpartum. Clinics in Dermatology 2016;34:344-52. [DOI: 10.1016/j.clindermatol.2016.02.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
35 Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:987-1019. [PMID: 19857207 DOI: 10.1111/j.1365-2133.2009.09505.x] [Cited by in Crossref: 308] [Cited by in F6Publishing: 241] [Article Influence: 28.0] [Reference Citation Analysis]
36 Wibaux C, Andrei I, Paccou J, Philippe P, Biver E, Duquesnoy B, Flipo RM. Pregnancy during TNFalpha antagonist therapy: beware the rifampin-oral contraceptive interaction. Report of two cases. Joint Bone Spine. 2010;77:268-270. [PMID: 20447852 DOI: 10.1016/j.jbspin.2010.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
37 Hazes JM, Coulie PG, Geenen V, Vermeire S, Carbonnel F, Louis E, Masson P, De Keyser F. Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford). 2011;50:1955-1968. [PMID: 21890617 DOI: 10.1093/rheumatology/ker302] [Cited by in Crossref: 80] [Cited by in F6Publishing: 57] [Article Influence: 8.0] [Reference Citation Analysis]
38 Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci. 2014;1317:32-38. [PMID: 24840548 DOI: 10.1111/nyas.12456] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
39 Borrego L. Etanercept en el embarazo y lactancia. Actas Dermo-Sifiliográficas 2010;101:97-101. [DOI: 10.1016/s0001-7310(10)70016-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
40 Naumann L, Feist E, Burmester GR. [Anticytokine therapy]. Internist (Berl) 2013;54:449-61; quiz 462-3. [PMID: 23463462 DOI: 10.1007/s00108-012-3202-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Babalola O, Strober BE. Management of psoriasis in pregnancy: Treatment of cutaneous disorders of pregnancy. Dermatol Ther 2013;26:285-92. [DOI: 10.1111/dth.12073] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
42 Fischer-Betz RE, Schneider M. [Biologics during pregnancy and breast--feeding]. Z Rheumatol 2010;69:780-7. [PMID: 21063826 DOI: 10.1007/s00393-010-0640-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
43 Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2014;43:78-84. [PMID: 24284028 DOI: 10.1016/j.reprotox.2013.11.004] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
44 Girolomoni G, Altomare G, Ayala F, Berardesca E, Calzavara-pinton P, Chimenti S, Peserico A, Puglisi Guerra A, Vena GA. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis. Immunopharmacology and Immunotoxicology 2012;34:548-60. [DOI: 10.3109/08923973.2011.653646] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
45 Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:823-826. [PMID: 21362710 DOI: 10.1136/ard.2010.140822] [Cited by in Crossref: 125] [Cited by in F6Publishing: 103] [Article Influence: 12.5] [Reference Citation Analysis]
46 Ali YM, Kuriya B, Orozco C, Cush JJ, Keystone EC. Can tumor necrosis factor inhibitors be safely used in pregnancy? J Rheumatol 2010;37:9-17. [PMID: 20008917 DOI: 10.3899/jrheum.090563] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
47 Ranchhod S, Gunn K, Fowke T, Davidson J, Lear C, Bai J, Bennet L, Mallard C, Gunn A, Dean J. Potential neuroprotective strategies for perinatal infection and inflammation. Int j dev neurosci 2015;45:44-54. [DOI: 10.1016/j.ijdevneu.2015.02.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
48 Abdolmohammadi-vahid S, Danaii S, Hamdi K, Jadidi-niaragh F, Ahmadi M, Yousefi M. Novel immunotherapeutic approaches for treatment of infertility. Biomedicine & Pharmacotherapy 2016;84:1449-59. [DOI: 10.1016/j.biopha.2016.10.062] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
49 Flynn A, Burke N, Byrne B, Gleeson N, Wynne B, Barnes L. Two case reports of generalized pustular psoriasis of pregnancy: Different outcomes. Obstet Med 2016;9:55-9. [PMID: 27512494 DOI: 10.1177/1753495X15626623] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
50 Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf. 2014;13:1699-1708. [PMID: 25406728 DOI: 10.1517/14740338.2014.973399] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
51 Abrouk M, Beroukhim K, Nakamura M, Zhu TH, Farahnik B, Singh R, Lee K, Koo J, Bhutani T. Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule. Int J Womens Dermatol 2017;3:S67-9. [PMID: 28492043 DOI: 10.1016/j.ijwd.2017.02.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Ostensen M, Förger F. Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol. 2011;23:293-298. [PMID: 21346578 DOI: 10.1097/bor.0b013e328344a732] [Cited by in Crossref: 37] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
53 Garip Y. Use of biologic agents for rheumatic diseases in pregnancy. WJR 2015;5:50. [DOI: 10.5499/wjr.v5.i2.50] [Reference Citation Analysis]
54 Prasad JD, Gunn KC, Davidson JO, Galinsky R, Graham SE, Berry MJ, Bennet L, Gunn AJ, Dean JM. Anti-Inflammatory Therapies for Treatment of Inflammation-Related Preterm Brain Injury. Int J Mol Sci 2021;22:4008. [PMID: 33924540 DOI: 10.3390/ijms22084008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 De Lorenzo R, Ramirez GA, Punzo D, Lorioli L, Rovelli R, Canti V, Barera G, Rovere-Querini P. Neonatal outcomes of children born to mothers on biological agents during pregnancy: State of the art and perspectives. Pharmacol Res 2020;152:104583. [PMID: 31816434 DOI: 10.1016/j.phrs.2019.104583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Nasef NA, Ferguson LR. Inflammatory bowel disease and pregnancy: overlapping pathways. Transl Res. 2012;160:65-83. [PMID: 22687963 DOI: 10.1016/j.trsl.2011.12.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
57 Pentšuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: New insights into developmental toxicity testing of monoclonal antibodies. Birth Defect Res B 2009;86:328-44. [DOI: 10.1002/bdrb.20201] [Cited by in Crossref: 177] [Cited by in F6Publishing: 138] [Article Influence: 14.8] [Reference Citation Analysis]
58 Hoffman MB, Farhangian M, Feldman SR. Psoriasis during pregnancy: characteristics and important management recommendations. Expert Review of Clinical Immunology 2015;11:709-20. [DOI: 10.1586/1744666x.2015.1037742] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
59 Belinchón I, Velasco M, Ara-Martín M, Armesto Alonso S, Baniandrés Rodríguez O, Ferrándiz Pulido L, García-Bustinduy M, Martínez-López JA, Martínez Sánchez N, Pérez Ferriols A, Pérez Pascual E, Rivera Díaz R, Ruiz-Villaverde R, Taberner Ferrer R, Vicente Villa A, Carrascosa JM. Management of Psoriasis During Preconception, Pregnancy, Postpartum, and Breastfeeding: A Consensus Statement. Actas Dermosifiliogr (Engl Ed) 2021;112:225-41. [PMID: 33065101 DOI: 10.1016/j.ad.2020.10.002] [Reference Citation Analysis]
60 Mena-vazquez N. Safety of biologic therapies during pregnancy in women with rheumatic disease. WJR 2015;5:82. [DOI: 10.5499/wjr.v5.i2.82] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
61 Ruiz V, Manubens E, Puig L. Psoriasis in pregnancy: a review (II). Actas Dermosifiliogr 2014;105:813-21. [PMID: 24314892 DOI: 10.1016/j.ad.2013.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
62 Bećarević M. Detrimental roles of TNF-alpha in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-alpha. J Thromb Thrombolysis 2017;44:565-70. [DOI: 10.1007/s11239-017-1571-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
63 Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy. Birth Defects Research Part A: Clinical and Molecular Teratology 2012;94:607-11. [DOI: 10.1002/bdra.23033] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
64 Brown SM, Aljefri K, Waas R, Hampton P. Systemic medications used in treatment of common dermatological conditions: safety profile with respect to pregnancy, breast feeding and content in seminal fluid. J Dermatolog Treat 2019;30:2-18. [PMID: 28092212 DOI: 10.1080/09546634.2016.1202402] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
65 Natsumi I, Matsukawa Y, Miyagawa K, Kodaira H, Tanaka T, Horikoshi A, Takeuchi J, Takei M, Maejima M, Akimoto J. Successful childbearing in two women with rheumatoid arthritis and a history of miscarriage after etanercept treatment. Rheumatol Int 2013;33:2433-5. [DOI: 10.1007/s00296-012-2433-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
66 Statkute L, Ruderman EM. Novel TNF antagonists for the treatment of rheumatoid arthritis. Expert Opinion on Investigational Drugs 2009;19:105-15. [DOI: 10.1517/13543780903438559] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
67 Bae YC, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo B, Kimball AB. Review of treatment options for psoriasis in pregnant or lactating women: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology 2012;67:459-77. [DOI: 10.1016/j.jaad.2011.07.039] [Cited by in Crossref: 73] [Cited by in F6Publishing: 44] [Article Influence: 8.1] [Reference Citation Analysis]
68 Wilmer E, Chai S, Kroumpouzos G. Drug safety: Pregnancy rating classifications and controversies. Clinics in Dermatology 2016;34:401-9. [DOI: 10.1016/j.clindermatol.2016.02.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]